GPC3-targeted CAR T cells (IL-15/IL-21 armored)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GPC3-targeted CAR T cells (IL-15/IL-21 armored), covering 2026-02-17 to 2026-02-17. Get the full timeline:
Most recent: Clinical Trial Update: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells [Phase 1]